Effect of therapeutic-dose heparin on severe acute kidney injury and death in noncritically ill patients hospitalized for COVID-19: a prespecified secondary analysis of the ACTIV4a and ATTACC randomized trial.
Nathaniel R SmilowitzErinn M HadeLucy Z KornblithLana A CastellucciMary CushmanMichael FarkouhMichelle N GongAnna HeathBeverly J HuntKeri S KimAndrei KindzelskiPatrick LawlerDavid E LeafEwan GoligherEric S LeiferBryan J McVerryHarmony R ReynoldsRyan ZarychanskiJudith S HochmanMatthew D NealJeffrey S BergerPublished in: Research and practice in thrombosis and haemostasis (2023)
Therapeutic-dose heparin was associated with a high probability of superiority to reduce the incidence of in-hospital severe AKI or death in patients hospitalized for COVID-19.
Keyphrases
- acute kidney injury
- end stage renal disease
- coronavirus disease
- ejection fraction
- newly diagnosed
- sars cov
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- healthcare
- venous thromboembolism
- emergency department
- growth factor
- patient reported outcomes
- patient reported
- drug induced
- acute care
- electronic health record